SOLARA Solara Active Pharma Sciences Q2 FY27 results (Jul–Sep 2026) and concall
Solara Active Pharma Sciences delivered its best quarter in five years for Q2 FY27, marked by robust revenue and EBITDA growth, and a return to profitability. The base business was the primary driver, while the Ibuprofen segment significantly narrowed its losses. Despite ongoing macroeconomic challenges like the West Asia crisis impacting raw material costs, the company improved its financial health through debt reduction and operational efficiencies, though trade receivables saw an increase.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY27: revenue up 32.8%, net profit up 380.0% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 300 | 273 | 319 | 314 | 349 +16% | 387 +42% | 382 +20% | 417 +33% |
| EBITDA | 58 | 45 | 57 | 35 | 37 −36% | 58 +29% | 62 +9% | 77 +120% |
| Net profit | 8 | -2 | 11 | -10 | -17 −312% | 10 +600% | 16 +45% | 28 +380% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
